標題: A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity
作者: Tseng, Feng-Jen
Liu, Yen-Ku
Chung, Yo-Shong
Lin, Yu-Ling
Chen, Chia-Hung
Wang, Wan-Yi
Chen, Yu-Cheng
Tsai, Nu-Man
Cheng, Tian-Lu
Pan, Ru-Yu
Hu, Tsung-Ming
Lee, Ru-Ping
Liao, Kuang-Wen
生物科技學系
分子醫學與生物工程研究所
Department of Biological Science and Technology
Institute of Molecular Medicine and Bioengineering
關鍵字: Vascular endothelial growth factor;Receptor binding domain of VEGF-A;Immunoglobulin;Fusion protein;Human umbilical vein endothelial cells
公開日期: 1-May-2011
摘要: Vascular endothelial growth factor (VEGF) promotes the growth of solid tumor mainly via VEGF receptor-1 and receptor-2, which are expressed preferentially in proliferating endothelial cells. Therefore, a strategy for simultaneous blockage of both VEGF receptors may have a useful therapeutic effect in tumor growth. In this study, we utilized a fusion protein which is composed of receptor binding domain of VEGF-A (RBDV) and the constant region fragment (Fc) of a human immunoglobulin G1 (IgG1), to interfere with the growth of human umbilical vein endothelial cells (HUVECs) via VEGF receptors. The results showed that RBDV-IgG1 Fc was able to bind with both VEGF receptor-1 and receptor-2. In addition, RBDV-IgG1 Fc could decrease VEGF-induced proliferation and tube formation among HUVECs. Moreover, the cytotoxic test showed RBDV-IgG1 Fc could also enhance the cytotoxic activity of human natural killing cells. The data are suggesting that the fusion protein, RBDV-IgG1 Fc, may have potential as an angiogenesis antagonist for future tumor therapy.
URI: http://dx.doi.org/10.1007/s10616-011-9340-2
http://hdl.handle.net/11536/8959
ISSN: 0920-9069
DOI: 10.1007/s10616-011-9340-2
期刊: CYTOTECHNOLOGY
Volume: 63
Issue: 3
起始頁: 285
結束頁: 293
Appears in Collections:Articles


Files in This Item:

  1. 000289798400009.pdf